Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype

Key Points

• To analyze the genomic profiling of endometrial cancer patients based on tumor stage, histology, and molecular subtype.
• Genomic profiling of 671 endometrial cancer patients from the ORIEN database.
• Identification of mutations and alterations in specific cancer-related genes.
• Analysis of biomarker patterns associated with different tumor stages and histologies.
• TP53 and ERBB2 mutations are predominantly found in advanced and non-endometrioid tumors.
• POLE, PTEN, and ARID1A mutations, along with high tumor mutational burden, are more frequent in early-stage endometrioid tumors.
• Distinct genomic alteration patterns are observed across TCGA molecular subtypes.